UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
The FDA cited manufacturing issues in turning down UCB’s application seeking approval for bimekizumab, an antibody drug developed to treat moderate-to-severe plaque psoriasis. Bimekizumab is […]